Skip to main content

Table 2 Number of evaluable patients (%) with stable disease or better response* by MIPI risk category [13,14]

From: Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis

  n/N (%) [n]
Treatment Low risk Intermediate risk High risk
Temsirolimus 175/75 mg 9/12 (75) 11/18 (61) 8/10 (80)
[5 PR, 4 SD] [1 CR, 5 PR, 5 SD] [1 PR, 7 SD]
Temsirolimus 175/25 mg 10/13 (77) 5/15 (33) 5/15 (33)
[2 PR, 8 SD] [1 PR, 4 SD] [5 SD]
INV therapy 4/11 (36) 8/20 (40) 0/9 (0)
[4 SD] [1 CR, 7 SD]  
  1. *Disease assessment was based on radiographic review by independent radiologists and review of clinical data by independent oncologists; evaluable patients were those with tumor assessment available.
  2. MIPI = Mantle Cell Lymphoma International Prognostic Index; PR = partial response; SD = stable disease ≥8 weeks; CR = complete response; INV = Investigator’s choice.